Molly Friedman, DO
Family Medicine · Twinsburg, OHNPI 1952487134
Payments from drug & device makers
Across 295 payments — averaging $16.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Lilly USA, LLC$674
- AstraZeneca$388
- Pfizer$342
- Astellas Pharma US Inc$321
- Novo Nordisk$255
- plus $2K from 32 others
What the payments were for
- Food & beverage$4,987100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 81 | $1,361 |
| Lilly USA, LLC | 43 | $674 |
| AstraZeneca | 20 | $388 |
| Pfizer | 21 | $342 |
| Astellas Pharma US Inc | 18 | $321 |
| Novo Nordisk | 17 | $255 |
| Exact Sciences | 11 | $196 |
| GSK | 12 | $194 |
| Amgen | 12 | $183 |
| Boehringer Ingelheim | 5 | $89 |
| Supernus Pharmaceuticals, Inc. | 5 | $80 |
| Currax Pharmaceuticals LLC | 5 | $65 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $56 |
| Amarin Pharma, Inc. | 3 | $52 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $52 |
| Novartis | 3 | $52 |
| Optinose US, Inc. | 2 | $51 |
| Lundbeck LLC | 3 | $49 |
| Xeris Pharmaceuticals, Inc. | 2 | $47 |
| Teva Pharmaceuticals USA, Inc. | 2 | $45 |
| Genentech USA, Inc. | 3 | $44 |
| Amneal Pharmaceuticals LLC | 2 | $41 |
| Dexcom, Inc. | 2 | $41 |
| Madrigal Pharmaceuticals | 1 | $35 |
| Idorsia Pharmaceuticals US Inc | 2 | $31 |
| Inspire Medical Systems, Inc. | 1 | $28 |
| Acella Pharmaceuticals, LLC | 1 | $26 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $25 |
| Merck | 1 | $22 |
| Vivus LLC | 1 | $21 |
| IBSA Pharma Inc. | 1 | $19 |
| Esperion Therapeutics, Inc. | 1 | $17 |
| Nabriva Therapeutics, PLC | 1 | $15 |
| Johnson & Johnson | 1 | $15 |
| Phadia US Inc. | 1 | $15 |
| Bavarian Nordic A/s | 1 | $14 |
| Ironshore Pharmaceuticals Inc. | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EUCRISA$127
How this compares
$4,987 in reported general payments places this provider in the 85th percentile of 3,983 family medicine providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 102 | $120,755 |
| TrulicityDulaglutide | 72 | $88,772 |
| OtezlaApremilast | 16 | $72,485 |
| OzempicSemaglutide | 54 | $66,371 |
| FarxigaDapagliflozin Propanediol | 28 | $39,666 |
| XareltoRivaroxaban | 25 | $34,700 |
| JanuviaSitagliptin Phosphate | 19 | $29,479 |
| JardianceEmpagliflozin | 20 | $20,832 |
| ProliaDenosumab | 11 | $19,760 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 30 | $19,674 |
| MounjaroTirzepatide | 11 | $17,072 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 23 | $15,610 |
| EntrestoSacubitril/Valsartan | 12 | $14,402 |
| Repatha SureclickEvolocumab | 14 | $14,319 |
| SynthroidLevothyroxine Sodium | 163 | $12,032 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $342 | $120,755102 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $674 | $105,84383 claims |
| AmgenOtezla, Prolia | $183 | $92,24627 claims |
| Novo NordiskOzempic | $255 | $66,37154 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $388 | $58,86966 claims |
| MerckJanuvia, Dulera | $22 | $38,39240 claims |
| Johnson & JohnsonXarelto | $15 | $34,70025 claims |
| GSKTrelegy Ellipta, Arnuity Ellipta | $194 | $23,42542 claims |
| Boehringer IngelheimJardiance | $89 | $20,83220 claims |
| NovartisEntresto | $52 | $14,40212 claims |
| AbbVieSynthroid | $1,361 | $12,032163 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $41 | $3,038404 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,983 family medicine providers in Ohio.
Other family medicine in Twinsburg
- Michael ButcherCincinnati$18.3M
- William RandallKettering$7.5M
- Paul NugentCincinnati$4.9M
- Steve ChoiDayton$4.8M
- Martin SchearDayton$2.2M
- Rajesh DavitCincinnati$2M
- Kwabena OtengSpringdale$2M
- Blaise GattoMoraine$1.8M
- Cathy GreiweColumbus$1.4M
- Brian BeesleyColumbus$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.